002817.SZ
Anhui Huangshan Capsule Co., Ltd. [002817.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002817.SZ Stock Summary
Top 10 Correlated ETFs
002817.SZ
Top 10 Correlated Stocks
002817.SZ
In the News
002817.SZ Financial details
Company Rating
Buy
Market Cap
2.65B
Income
62.28M
Revenue
402.96M
Book val./share
3.01
Cash/share
1.52
Dividend
0.08
Dividend %
0.9%
Employees
749
Optionable
No
Shortable
Yes
Earnings
28 Apr 2021
P/E
39.75
Forward P/E
-
PEG
39.09
P/S
6.14
P/B
2.94
P/C
5.83
P/FCF
34.63
Quick Ratio
2.67
Current Ratio
4.22
Debt / Equity
0.3
LT Debt / Equity
0.07
-
-
EPS (TTM)
0.24
EPS next Y
-
EPS next Q
-
EPS this Y
25.7%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
4.17%
Revenue last 5Y
5.85%
Revenue Q/Q
-11.82%
EPS Q/Q
-5.49%
-
-
-
-
SMA20
-4.62%
SMA50
-1%
SMA100
-3.58%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
8%
ROC
0.07%
Gross Margin
29%
Oper. Margin
17%
Profit Margin
15%
Payout
34%
Shs Outstand
299.1M
Shs Float
165.98M
-
-
-
-
Target Price
-
52W Range
5.907142-13.21
52W High
-31.85%
52W Low
+77.2%
RSI
44.01
Rel Volume
0.74
Avg Volume
5.85M
Volume
4.31M
Perf Week
-0.23%
Perf Month
-3.06%
Perf Quarter
26.93%
Perf Half Y
23.4%
-
-
-
-
Beta
0.441558
-
-
Volatility
0.11%, 0.23%
Prev Close
-1.12%
Price
8.86
Change
-2.32%
002817.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.35 | 1.36 | 1.52 | 1.51 | 1.79 | |
| Net income per share | 0.22 | 0.17 | 0.18 | 0.21 | 0.27 | |
| Operating cash flow per share | 0.21 | 0.13 | 0.24 | 0.3 | 0.41 | |
| Free cash flow per share | 0.08 | -0.03 | 0.13 | -0.15 | 0.05 | |
| Cash per share | 1.17 | 1.58 | 1.35 | 1.61 | 1.93 | |
| Book value per share | 3.14 | 3.2 | 3.38 | 3.6 | 3.83 | |
| Tangible book value per share | 3.07 | 3.15 | 3.32 | 3.54 | 3.75 | |
| Share holders equity per share | 3.14 | 3.2 | 3.38 | 3.6 | 3.83 | |
| Interest debt per share | 0 | 0.01 | 0 | 0.08 | 0.36 | |
| Market cap | 1.84B | 1.06B | 1.38B | 1.36B | 1.81B | |
| Enterprise value | 1.6B | 717.38M | 1.17B | 1.14B | 1.54B | |
| P/E ratio | 39.73 | 29.42 | 35.27 | 30.15 | 31.73 | |
| Price to sales ratio | 6.45 | 3.59 | 4.24 | 4.27 | 4.75 | |
| POCF ratio | 41.52 | 38.45 | 26.53 | 21.76 | 20.97 | |
| PFCF ratio | 108.79 | -184.89 | 50.52 | -43.92 | 176.12 | |
| P/B Ratio | 2.77 | 1.53 | 1.9 | 1.79 | 2.23 | |
| PTB ratio | 2.77 | 1.53 | 1.9 | 1.79 | 2.23 | |
| EV to sales | 5.58 | 2.43 | 3.6 | 3.56 | 4.04 | |
| Enterprise value over EBITDA | 20.36 | 10.71 | 15.72 | 14.1 | 15.86 | |
| EV to operating cash flow | 35.95 | 26.06 | 22.54 | 18.15 | 17.84 | |
| EV to free cash flow | 94.19 | -125.34 | 42.93 | -36.64 | 149.87 | |
| Earnings yield | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Free cash flow yield | 0.01 | -0.01 | 0.02 | -0.02 | 0.01 | |
| Debt to equity | 0.11 | 0.12 | 0.15 | 0.2 | 0.3 | |
| Debt to assets | 0.1 | 0.11 | 0.13 | 0.16 | 0.23 | |
| Net debt to EBITDA | -3.16 | -5.09 | -2.78 | -2.8 | -2.78 | |
| Current ratio | 9.56 | 8.41 | 6.83 | 4.85 | 4.38 | |
| Interest coverage | 52.19 | 47.32 | 85.53 | 176.42 | 286.71 | |
| Income quality | 0.96 | 0.77 | 1.33 | 1.39 | 1.51 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.25 | 0.28 | 0.19 | 0.18 | 0.19 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.03 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.04 | 0.03 | 0.04 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.62 | -1.21 | -0.47 | -1.5 | -0.88 | |
| Capex to revenue | -0.1 | -0.11 | -0.08 | -0.29 | -0.2 | |
| Capex to depreciation | -1.16 | -1.33 | -0.86 | -3.21 | -2.26 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.94 | 3.46 | 3.73 | 4.16 | 4.81 | |
| ROIC | 0.18 | 0.5 | 0.08 | 0.1 | 0.18 | |
| Return on tangible assets | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | |
| Graham Net | 0.97 | 1.34 | 1.03 | 1.07 | 1 | |
| Working capital | 429.94M | 445.02M | 477.88M | 442.3M | 493.76M | |
| Tangible asset value | 649.84M | 680.69M | 710.8M | 749.99M | 793.48M | |
| Net current asset value | 407.54M | 421.66M | 454.38M | 406.37M | 395.81M | |
| Invested capital | 0 | 0 | 0 | 0.02 | 0.09 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 26.28M | 34.2M | 47.15M | 68.45M | 94.93M | |
| Average inventory | 56.14M | 61.83M | 68.76M | 73.05M | 80.88M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 54.72 | 76.06 | 93.71 | 140.14 | 150.17 | |
| Days of inventory on hand | 122.13 | 115.87 | 131.96 | 119.07 | 128.22 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 6.67 | 4.8 | 3.89 | 2.6 | 2.43 | |
| Inventory turnover | 2.99 | 3.15 | 2.77 | 3.07 | 2.85 | |
| ROE | 0.07 | 0.05 | 0.05 | 0.06 | 0.07 | |
| Capex per share | -0.13 | -0.15 | -0.12 | -0.44 | -0.36 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.37 | 0.46 | 0.36 | 0.38 | 0.34 | |
| Net income per share | 0.07 | 0.06 | 0.05 | 0.06 | 0.06 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0.2 | 0.06 | -0.1 | 0.15 | |
| Cash per share | 1.56 | 1.83 | 1.53 | 1.37 | 1.52 | |
| Book value per share | 3.56 | 3.62 | 2.95 | 2.95 | 3.01 | |
| Tangible book value per share | 3.49 | 3.55 | 2.89 | 2.89 | 2.95 | |
| Share holders equity per share | 3.56 | 3.62 | 2.95 | 2.95 | 3.01 | |
| Interest debt per share | 0.29 | 0.34 | 0.27 | 0.27 | 0.26 | |
| Market cap | 1.65B | 1.91B | 2.59B | 2.02B | 2.31B | |
| Enterprise value | 1.46B | 1.64B | 2.43B | 1.92B | 2.1B | |
| P/E ratio | 25.62 | 33.64 | 46.35 | 28.78 | 34.79 | |
| Price to sales ratio | 19.87 | 18.74 | 25.57 | 19.02 | 24.64 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | -1.61K | 42.32 | 149.28 | -75.38 | 56.44 | |
| P/B Ratio | 2.07 | 2.36 | 3.14 | 2.45 | 2.74 | |
| PTB ratio | 2.07 | 2.36 | 3.14 | 2.45 | 2.74 | |
| EV to sales | 17.63 | 16.1 | 23.98 | 18.05 | 22.39 | |
| Enterprise value over EBITDA | 80.53 | 104.01 | 159.56 | 96.28 | 118.65 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | -1.43K | 36.35 | 139.99 | -71.54 | 51.28 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0.02 | 0.01 | -0.01 | 0.02 | |
| Debt to equity | 0.23 | 0.3 | 0.32 | 0.3 | 0.3 | |
| Debt to assets | 0.19 | 0.23 | 0.24 | 0.23 | 0.23 | |
| Net debt to EBITDA | -10.25 | -17.08 | -10.59 | -5.17 | -11.95 | |
| Current ratio | 5.85 | 4.38 | 4.19 | 4.43 | 4.22 | |
| Interest coverage | 323.55 | 278.19 | 527.59 | 252.73 | 337.7 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
| Payout ratio | 0 | 0.14 | 0.05 | 1.01 | 0.04 | |
| Sales general and administrative to revenue | 0.19 | -0.11 | 0.05 | -0.02 | 0.14 | |
| Research and developement to revenue | 0.05 | 0.02 | 0.04 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.02 | -0.09 | -0.06 | -0.25 | -0.03 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.4 | 2.27 | 1.82 | 2.04 | 2 | |
| ROIC | 0.03 | 0.05 | 0.03 | 0.03 | 0.04 | |
| Return on tangible assets | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Graham Net | 0.98 | 0.94 | 0.76 | 0.68 | 0.82 | |
| Working capital | 492.63M | 493.76M | 514.06M | 497.86M | 512.09M | |
| Tangible asset value | 781.38M | 793.48M | 807.54M | 807.34M | 824.39M | |
| Net current asset value | 410.97M | 395.81M | 414.66M | 397.13M | 418.94M | |
| Invested capital | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 79.83M | 89.17M | 114.61M | 114.51M | 108.23M | |
| Average inventory | 97.05M | 99.19M | 92.39M | 98.89M | 109.72M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 124.71 | 138.28 | 149.14 | 126.05 | 150.78 | |
| Days of inventory on hand | 186.28 | 118.06 | 114.09 | 123.25 | 158.09 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.72 | 0.65 | 0.6 | 0.71 | 0.6 | |
| Inventory turnover | 0.48 | 0.76 | 0.79 | 0.73 | 0.57 | |
| ROE | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex per share | -0.01 | -0.04 | -0.02 | -0.09 | -0.01 |
002817.SZ Frequently Asked Questions
What is Anhui Huangshan Capsule Co., Ltd. stock symbol ?
Anhui Huangshan Capsule Co., Ltd. is a CN stock and trading under the symbol 002817.SZ
What is Anhui Huangshan Capsule Co., Ltd. stock quote today ?
Anhui Huangshan Capsule Co., Ltd. stock price is $8.86 today.
Is Anhui Huangshan Capsule Co., Ltd. stock public?
Yes, Anhui Huangshan Capsule Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 5.85M
- Market Capitalization 2.65B
- Employee 749
- CEO Mr. Chao Biao Yu
- Headquarters Xuancheng,CN
- IPO Date 2016-10-25
-
Website
https://www.hsjn.com 
Anhui Huangshan Capsule Co., Ltd. manufactures and sells hollow and enteric hollow capsules in China. It offers entersoluble vacant gelatin capsules, vacant gelatin capsules, vegetable entersoluble capsules, colon soluble vacant gelatin capsules, hydroxypropyl methyl cellulose and hydroxypropyl starch hollow capsules, and pulluan capsules. The company was founded in 1989 and is based in Xuancheng, China.
